Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30428166 | 0.81 | CCNC (0.36) | CCNCCDK8 | |
| SCHEMBL14905891 | 0.77 | — | — | |
| SCHEMBL3143437 | 0.77 | — | — | |
| SCHEMBL30428415 | 0.76 | BACE1 (0.35) | — | |
| SCHEMBL20666475 | 0.75 | CCNC (0.34) | CCNCCDK8 | |
| SCHEMBL29087151 | 0.75 | — | — | |
| SCHEMBL22771465 | 0.75 | — | — | |
| SCHEMBL27412666 | 0.75 | — | — | |
| SCHEMBL4062968 | 0.75 | — | — | |
| SCHEMBL2050872 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20200291020-A1 | NEW [1,6]NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM RCV GMBH & CO. KG (AT) | 2020-09-17 | — | — | US | disclosed |
| WO-2019068613-A1 | NEW [1,6]NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-11 | — | — | WO | disclosed |
| US-5006511-A | Treating hypertension, congestive heart failure | MERCK & CO., INC. (US) | 1991-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291020-A1 | NEW [1,6]NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | CDK9, CDK19, CDK8 | CCNC 39/4885CDK8 3/4885BRD4 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.